Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilavonemab in Progressive Supranuclear Palsy
NCT02494024Phase 1Completed
- Sponsor
- C2N Diagnostics
- Start
- Jul 2015
- Primary completion
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tilavonemab in progressive supranuclear palsy (PSP) (5 arms), sponsored by C2N Diagnostics. Primary endpoint: Safety and tolerability at 4 months. Started Jul 2015; status: completed.
02
Drugs
tilavonemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT02494024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02494024.